{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:03:34Z","timestamp":1791302614745,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.ctrv.2015.11.005","type":"journal-article","created":{"date-parts":[[2015,11,22]],"date-time":"2015-11-22T06:04:12Z","timestamp":1448172252000},"page":"3-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":165,"special_numbering":"C","title":["Low dose cyclophosphamide: Mechanisms of T cell modulation"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0958-6314","authenticated-orcid":false,"given":"Mutsa Tatenda","family":"Madondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6889-3667","authenticated-orcid":false,"given":"Magdalena","family":"Plebanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4613","key":"10.1016\/j.ctrv.2015.11.005_b0005","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/181931a0","article-title":"Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B 518-ASTA) in experimental tumours of the rat","volume":"181","author":"Arnold","year":"1958","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ctrv.2015.11.005_b0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0090-8258(76)90006-8","article-title":"The treatment of advanced ovarian carcinoma with high dose, intravenous cyclophosphamide","volume":"4","author":"Geisler","year":"1976","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2015.11.005_b0015","first-page":"413","article-title":"Intermittent high-dose cyclophosphamide chemotherapy for small cell carcinoma of the lung","volume":"62","author":"Ettinger","year":"1978","journal-title":"Cancer Treat Rep"},{"issue":"6","key":"10.1016\/j.ctrv.2015.11.005_b0020","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/1097-0142(19820915)50:6<1051::AID-CNCR2820500605>3.0.CO;2-X","article-title":"Intermittent high-dose cyclophosphamide with and without prednisolone: a study of the relationships between toxicity, response and survival in metastatic lung cancer","volume":"50","author":"Thatcher","year":"1982","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2015.11.005_b0025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000225136","article-title":"High dose imtermittent intravenous cyclophosphamide in non-Hodgkin\u2019s lymphomas: long-term patient follow-up","volume":"33","author":"O\u2019Connell","year":"1976","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.ctrv.2015.11.005_b0030","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0022-5347(17)41173-6","article-title":"Urological complications of cyclophosphamide","volume":"141","author":"Levine","year":"1989","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ctrv.2015.11.005_b0035","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/1097-0142(197906)43:6<2223::AID-CNCR2820430610>3.0.CO;2-Y","article-title":"Cyclophosphamide-induced cardiomyopathy: a report of two cases and review of the English literature","volume":"43","author":"Mills","year":"1979","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2015.11.005_b0040","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/archinte.1981.00340060066015","article-title":"Cardiotoxicity associated with high-dose cyclophosphamide therapy","volume":"141","author":"Gottdiener","year":"1981","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.ctrv.2015.11.005_b0045","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/0961203308093828","article-title":"High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures","volume":"17","author":"Dussan","year":"2008","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.ctrv.2015.11.005_b0050","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/sj.bmt.1703874","article-title":"High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin\u2019s lymphoma","volume":"31","author":"Rossi","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.ctrv.2015.11.005_b0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/annonc\/mdf013","article-title":"Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels","volume":"13","author":"Colleoni","year":"2002","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2015.11.005_b0060","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00262-011-1106-3","article-title":"Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome","volume":"61","author":"Ge","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2015.11.005_b0065","doi-asserted-by":"crossref","DOI":"10.1111\/ajco.12074","article-title":"Oral cyclophosphamide in recurrent ovarian cancer","author":"Handolias","year":"2013","journal-title":"Asia Pac J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2015.11.005_b0070","first-page":"2344","article-title":"Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation","volume":"49","author":"Clarke","year":"1989","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2015.11.005_b0075","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0022-3565(24)38043-7","article-title":"In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity","volume":"288","author":"Yu","year":"1999","journal-title":"J Pharmacol Experiment Ther"},{"issue":"4","key":"10.1016\/j.ctrv.2015.11.005_b0080","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/03602530500364023","article-title":"Metabolism and transport of oxazaphosphorines and the clinical implications","volume":"37","author":"Zhang","year":"2005","journal-title":"Drug Metab Rev"},{"issue":"11","key":"10.1016\/j.ctrv.2015.11.005_b0085","first-page":"5156","article-title":"Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia","volume":"44","author":"Hilton","year":"1984","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.ctrv.2015.11.005_b0090","first-page":"3180","article-title":"Effect of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of human multipotent and committed hematopoietic progenitor cells and malignant blood cells to oxazaphosphorines","volume":"47","author":"Kohn","year":"1987","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2015.11.005_b0095","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0090-9556(25)07199-5","article-title":"Glutathione conjugation with phosphoramide mustard and cyclophosphamide. A mechanistic study using tandem mass spectrometry","volume":"19","author":"Yuan","year":"1991","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.ctrv.2015.11.005_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1383-5718(99)00052-2","article-title":"Role of glutathione on acrolein-induced cytotoxicity and mutagenicity in Escherichia coli","volume":"442","author":"Nunoshiba","year":"1999","journal-title":"Mutat Res"},{"issue":"2\u20133","key":"10.1016\/j.ctrv.2015.11.005_b0105","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0014-5793(97)00612-1","article-title":"Cytosolic NAD+ content strictly depends on ATP concentration in isolated liver cells","volume":"410","author":"Devin","year":"1997","journal-title":"FEBS Lett"},{"issue":"9","key":"10.1016\/j.ctrv.2015.11.005_b0110","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1128\/AEM.56.9.2591-2599.1990","article-title":"Coenzyme A-acylating aldehyde dehydrogenase from Clostridium beijerinckii NRRL B592","volume":"56","author":"Yan","year":"1990","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.ctrv.2015.11.005_b0115","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1146\/annurev.bi.52.070183.003431","article-title":"Glutathione","volume":"52","author":"Meister","year":"1983","journal-title":"Annu Rev Biochem"},{"issue":"21","key":"10.1016\/j.ctrv.2015.11.005_b0120","doi-asserted-by":"crossref","first-page":"7218","DOI":"10.1021\/jo980546s","article-title":"Isophosphoramide mustard and its mechanism of bisalkylation","volume":"63","author":"Springer","year":"1998","journal-title":"J Org Chem"},{"issue":"10","key":"10.1016\/j.ctrv.2015.11.005_b0125","first-page":"5029","article-title":"Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells","volume":"46","author":"Crook","year":"1986","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2015.11.005_b0130","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF00686152","article-title":"Cytotoxicity, DNA cross-linking, and DNA single-strand breaks induced by cyclophosphamide in a rat leukemia in vivo","volume":"31","author":"Wang","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2015.11.005_b0135","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1038\/cddis.2011.70","article-title":"Mechanism of cell death resulting from DNA interstrand cross-linking in mammalian cells","volume":"2","author":"Osawa","year":"2011","journal-title":"Cell Death Dis"},{"issue":"1\u20132","key":"10.1016\/j.ctrv.2015.11.005_b0140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0300-483X(97)00086-3","article-title":"Relationships between cell density, glutathione and proliferation of A549 human lung adenocarcinoma cells treated with acrolein","volume":"122","author":"Horton","year":"1997","journal-title":"Toxicology"},{"issue":"1","key":"10.1016\/j.ctrv.2015.11.005_b0145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/jpet.106.114678","article-title":"Inhibition of acrolein-induced apoptosis by the antioxidant N-acetylcysteine","volume":"321","author":"Tanel","year":"2007","journal-title":"J Pharmacol Experiment Ther"},{"issue":"2","key":"10.1016\/j.ctrv.2015.11.005_b0150","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0197-0186(01)00012-2","article-title":"Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease","volume":"39","author":"Pocernich","year":"2001","journal-title":"Neurochem Int"},{"issue":"1","key":"10.1016\/j.ctrv.2015.11.005_b0155","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/toxsci\/57.1.6","article-title":"The molecular effects of acrolein","volume":"57","author":"Kehrer","year":"2000","journal-title":"Toxicol Sci"},{"issue":"14","key":"10.1016\/j.ctrv.2015.11.005_b0160","doi-asserted-by":"crossref","first-page":"9200","DOI":"10.1074\/jbc.274.14.9200","article-title":"Acrolein causes inhibitor kappaB-independent decreases in nuclear factor kappaB activation in human lung adenocarcinoma (A549) cells","volume":"274","author":"Horton","year":"1999","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.ctrv.2015.11.005_b0165","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.toxlet.2014.06.021","article-title":"Acrolein induced both pulmonary inflammation and the death of lung epithelial cells","volume":"229","author":"Sun","year":"2014","journal-title":"Toxicol Lett"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2015.11.005_b0170","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/S0092-8674(02)00703-1","article-title":"Missing pieces in the NF-kappaB puzzle","volume":"109","author":"Ghosh","year":"2002","journal-title":"Cell"},{"issue":"6642","key":"10.1016\/j.ctrv.2015.11.005_b0175","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/41493","article-title":"A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB","volume":"388","author":"DiDonato","year":"1997","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ctrv.2015.11.005_b0180","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/cr.2010.178","article-title":"Crosstalk of reactive oxygen species and NF-kappaB signaling","volume":"21","author":"Morgan","year":"2011","journal-title":"Cell Res"},{"issue":"5","key":"10.1016\/j.ctrv.2015.11.005_b0185","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10565-006-0078-0","article-title":"Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation","volume":"23","author":"Korkmaz","year":"2007","journal-title":"Cell Biol Toxicol"},{"issue":"7405","key":"10.1016\/j.ctrv.2015.11.005_b0190","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature11043","article-title":"SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation","volume":"487","author":"Barber","year":"2012","journal-title":"Nature"},{"issue":"7046","key":"10.1016\/j.ctrv.2015.11.005_b0195","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nature03672","article-title":"Global histone modification patterns predict risk of prostate cancer recurrence","volume":"435","author":"Seligson","year":"2005","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ctrv.2015.11.005_b0200","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1200\/JCO.2009.24.5639","article-title":"Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704","volume":"28","author":"Manuyakorn","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.11.005_b0205","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1038\/bcj.2013.66","article-title":"Alkylating agents induce histone H3K18 hyperacetylation and potentiate HDAC inhibitor-mediated global histone acetylation and cytotoxicity in mantle cell lymphoma","volume":"3","author":"Hiraoka","year":"2013","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.ctrv.2015.11.005_b0210","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1172\/JCI60806","article-title":"HDAC3 is essential for DNA replication in hematopoietic progenitor cells","volume":"123","author":"Summers","year":"2013","journal-title":"J Clin Investig"},{"issue":"3","key":"10.1016\/j.ctrv.2015.11.005_b0215","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bbrc.2006.03.018","article-title":"Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy","volume":"343","author":"Needham","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"44","key":"10.1016\/j.ctrv.2015.11.005_b0220","doi-asserted-by":"crossref","first-page":"17945","DOI":"10.1073\/pnas.1316796110","article-title":"Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans","volume":"110","author":"Sugiyama","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.ctrv.2015.11.005_b0225","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.4049\/jimmunol.1000652","article-title":"NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses","volume":"186","author":"Salagianni","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2015.11.005_b0230","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-1-61737-979-6_14","article-title":"Depletion of human regulatory T cells","volume":"707","author":"Hobeika","year":"2011","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.ctrv.2015.11.005_b0235","first-page":"87","article-title":"Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden","volume":"65","author":"Awwad","year":"1988","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.ctrv.2015.11.005_b0240","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.155.4.1063","article-title":"Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells","volume":"155","author":"North","year":"1982","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.ctrv.2015.11.005_b0245","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.ctrv.2015.11.005_b0250","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2015.11.005_b0255","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"10.1016\/j.ctrv.2015.11.005_b0260","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00262-008-0628-9","article-title":"Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy","volume":"58","author":"van der Most","year":"2009","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"10.1016\/j.ctrv.2015.11.005_b0265","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1158\/0008-5472.CAN-10-0283","article-title":"Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2015.11.005_b0270","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.clim.2013.07.003","article-title":"Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment","volume":"149","author":"Govindaraj","year":"2013","journal-title":"Clinical Immunol"},{"key":"10.1016\/j.ctrv.2015.11.005_b0275","doi-asserted-by":"crossref","DOI":"10.1002\/eji.201444879","article-title":"Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis","author":"Dimeloe","year":"2014","journal-title":"Eur J Immunol"},{"issue":"12","key":"10.1016\/j.ctrv.2015.11.005_b0280","doi-asserted-by":"crossref","first-page":"e83384","DOI":"10.1371\/journal.pone.0083384","article-title":"Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response","volume":"8","author":"Heylmann","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ctrv.2015.11.005_b0285","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/intimm\/dxq001","article-title":"GITR engagement preferentially enhances proliferation of functionally competent CD4+CD25+FoxP3+ regulatory T cells","volume":"22","author":"Liao","year":"2010","journal-title":"Int Immunol"},{"issue":"6","key":"10.1016\/j.ctrv.2015.11.005_b0290","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood.V95.6.2024","article-title":"Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer","volume":"95","author":"Schiavoni","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2015.11.005_b0295","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00262-001-0237-3","article-title":"Th2\/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model","volume":"50","author":"Matar","year":"2002","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.ctrv.2015.11.005_b0300","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/0008-5472.CAN-10-1259","article-title":"Cyclophosphamide induces differentiation of Th17 cells in cancer patients","volume":"71","author":"Viaud","year":"2011","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2015.11.005_b0305","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood-2009-06-224246","article-title":"Th17 cells in ovarian cancer","volume":"114","author":"Munn","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2015.11.005_b0310","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2009-03-208249","article-title":"Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments","volume":"114","author":"Kryczek","year":"2009","journal-title":"Blood"},{"issue":"2 Pt 1","key":"10.1016\/j.ctrv.2015.11.005_b0315","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/1078-0432.CCR-06-1209","article-title":"Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration","volume":"13","author":"Bracci","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ctrv.2015.11.005_b0320","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1158\/0008-5472.CAN-05-0646","article-title":"Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase","volume":"65","author":"Loeffler","year":"2005","journal-title":"Cancer Res"},{"issue":"25","key":"10.1016\/j.ctrv.2015.11.005_b0325","doi-asserted-by":"crossref","first-page":"16186","DOI":"10.1073\/pnas.252464599","article-title":"Nitric oxide preferentially induces type 1 T cell differentiation by selectively up-regulating IL-12 receptor beta 2 expression via cGMP","volume":"99","author":"Niedbala","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6161","key":"10.1016\/j.ctrv.2015.11.005_b0330","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.1240537","article-title":"The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide","volume":"342","author":"Viaud","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2015.11.005_b0335","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6793-9-6","article-title":"Intestinal barrier function in response to abundant or depleted mucosal glutathione in Salmonella-infected rats","volume":"9","author":"van Ampting","year":"2009","journal-title":"BMC Physiol"},{"issue":"2","key":"10.1016\/j.ctrv.2015.11.005_b0340","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.canlet.2014.07.033","article-title":"Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model","volume":"353","author":"Wu","year":"2014","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.ctrv.2015.11.005_b0345","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/2162402X.2015.1005521","article-title":"Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+ T-cell responses and immune memory","volume":"4","author":"Wu","year":"2015","journal-title":"Oncoimmunology"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215002030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215002030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T13:34:29Z","timestamp":1748698469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737215002030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":69,"alternative-id":["S0305737215002030"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.11.005","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low dose cyclophosphamide: Mechanisms of T cell modulation","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}